New agonist- and antagonist-based treatment approaches for advanced prostate cancer

Journal of International Medical Research

Volumn 40, Issue 4, 2012, Pages 1217-1226

  Xu, Y ^a,b   Jiang, Y F ^a   Wu, B ^a  

^a NANTONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Agonist; Androgen; Antagonist; Bombesin gastrin releasing peptide; Growth hormone releasing hormone (GHRH); Lutenizing hormone releasing hormone (LHRH); Prostate cancer; Somatostatin

Indexed keywords

AN 215; ANGIOPEPTIN; BOMBESIN DERIVATIVE; DEGARELIX; GONADORELIN AGONIST; GOSERELIN; GROWTH HORMONE RELEASING HORMONE ANTAGONIST; LEUPRORELIN; MZ J 7 138; OCTREOTIDE; PEPTIDE HORMONE ANTAGONIST; RC 3095; RC 3940 II; RC 3950; UNCLASSIFIED DRUG; VAPREOTIDE;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; BURNING SENSATION; CANCER COMBINATION CHEMOTHERAPY; CLOUDY URINE; CYSTALGIA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DYSURIA; HAIR LOSS; HEMATURIA; HOT FLUSH; HUMAN; IMPOTENCE; INJECTION SITE REACTION; LIBIDO DISORDER; MICTURITION DISORDER; NONHUMAN; OLIGURIA; OSTEOPENIA; PROSTATE CANCER; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84867569104     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/147323001204000401     Document Type: Review

References (72)

1. American Cancer Society: Cancer Facts and Figures 2010. Atlanta: American Cancer Society, 2010.
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225 249.
3. Quinn M, Babb P: Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 2002; 90: 162 - 173.
4. Zhang L, Wu S, Guo LR, et al: Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China. Asian J Androl 2009; 11: 9-13.
5. Gann PH, Hennekens CH, Ma J, et al: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996; 88: 1118-1126. (Pubitemid 26274606)
6. Shen MM, Abate-Shen C: Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010; 24: 1967 - 2000.
7. Sriprasad S, Feneley MR, Thompson PM: History of prostate cancer treatment. Surg Oncol 2009; 18: 185-191.
8. Perlmutter MA, Lepor H: Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol 2007; 9( suppl 1): S3 - S8.
9. Hou ZJ, Li YQ: Proteomics and its application in the research of prostatic carcinoma. Zhonghua Nan Ke Xue 2006; 12: 358 - 361 [in Chinese, English abstract].
10. Collette L, Fossa SD, Oosterhof GON, et al: Baseline quality of life measured with the EORTC QLQ-C30 helps to select a subset of 'good prognosis' metastatic hormone refractory prostate cancer patients. Eur J Cancer 2001; 37( suppl 6): S218.
11. Bott SR, Birtle AJ, Taylor CJ, et al: Prostate cancer management: (1) an update on localised disease. Postgrad Med J 2003; 79: 575 580.
12. Conn PM, Crowley WF Jr: Gonadotropinreleasing hormone and its analogs. Annu Rev Med 1994; 45: 391 - 405.
13. Tolis G, Ackman D, Stellos A, ef al: Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormonereleasing hormone agonists. Proc Natl Acad Sci USA 1982; 79: 1658 - 1662.
14. Schally AV, Comaru-Schally AM, Plonowski A, et al: Peptide analogs in the therapy of prostate cancer. Prostate 2000; 45: 158 - 166.
15. Schally AV, Comaru-Schally AM: Hypothalamic and other peptide hormones. In: Cancer Medicine, 7th edn (Holland JF, Freie E, Kufe DW, et al, eds). Hamilton: BC Decker; 2006; pp 802 816.
16. 6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1981; 78: 6509 - 6512.
17. Choi S, Lee AK: Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer. Drug Heaithc Patient Saf 2011; 3: 107 - 119.
18. Crawford ED, Hou AH: The role of LHRH antagonists in the treatment of prostate cancer. Oncology (Williston Park) 2009; 23: 626 - 630.
19. Crawford ED: Hormonal therapy in prostate cancer historical approaches. Rev Urol 2004; 6( suppl 7): S3-S11.
20. Hellerstedt BA, Pienta KJ: The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52: 154 - 179.
21. Van Poppel H, Nilsson S: Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 2008; 71: 1001 - 1006.
22. Tan O, Bukulmez O: Biochemistry, molecular biology and cell biology of gonadotropinreleasing hormone antagonists. Curr Opin Obstet Gynecol 2011; 23: 238 - 244.
23. Limonta P, Moretti RM, Marelli MM, et al: The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 1999; 140: 5250-5256.
24. Princivalle M, Broqua P, White R, et al: Rapid suppression of plasma testosterone levels and tumor growth in the Dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J Pharmacol Exp Ther 2007; 320:1113-1118. (Pubitemid 46294055)
25. Gittelman M, Pommerville PJ, Persson BE, et al: A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008; 180: 1986 - 1992.
26. Klotz L, Boccon-Gibod L, Shore ND, et al: The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallelgroup phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531 - 1538.
27. Van Poppel H, Tombal B, de la Rosette JJ, et al: Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker - results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008; 54: 805 - 813.
28. Pommerville PJ, de Boer JG: GnRH antagonists in the treatment of advanced prostate cancer. Can J Urol 2010; 17: 5063 - 5070.
29. Merali Z, Mcintosh J, Anisman H: Role of bombesin-related peptides in the control of food intake. Neuropeptides 1999; 33: 376 - 386.
30. Puccio F, Lehy T: Bombesin ingestion stimulates epithelial digestive cell proliferation in suckling rats. Am J Physiol 1989; 256: G328 - G334.
31. Casanueva FF, Perez FR, Casabiell X, et al: Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines. Proc Natl Acad Sci USA 1996; 93: 1406-1411. (Pubitemid 26075135)
32. Wang QJ, Knezetic JA, Schally AV, et al: Bombesin may stimulate proliferation of human pancreatic cancer cells through an autocrine pathway. Int J Cancer 1996; 68: 528 534.
33. Aprikian AG, Han K, Guy L, et al: Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer. Prostate Suppl 1998; 8: 52 - 61.
34. 4) bombesin by tumor cells. Prostate 1994; 25: 29 - 38.
35. Markwalder R, Reubi JC: Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999; 59: 1152-1159. (Pubitemid 29135980)
36. De Vincentis G, Scopinaro F, Varvarigou A, et al: Phase I trial of technetium [Leu 13] bombesin as cancer seeking agent: possible scintigraphic guide for surgery? Tumori 2002; 88: S28 - S30.
37. Faintuch BL, Teodoro R, Duatti A, et al: Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Nucl Med Biol 2008; 35: 401-411. (Pubitemid 351637643)
38. Ananias HJ, de Jong IJ, Dierckx RA, et al: Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals. Curr Pharm Des 2008; 14: 3033 - 3047.
39. Stangelberger A, Schally AV, Letsch M, et al: Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. Int J Cancer 2006; 118: 222 - 229.
40. Stangelberger A, Schally AV, Varga JL, et al: Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clin Cancer Res 2005; 11: 49 - 57.
41. Stangelberger A, Schally AV, Varga JL, et al: Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling. Eur J Cancer 2005; 41: 2735 - 2744.
42. Stangelberger A, Schally AV, Varga JL, et al: Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate 2005; 64: 303 - 315.
43. 2 or its derivatives. Proc Natl Acad Sci USA 1994; 91: 12664 - 12668.
44. Koppán M, Halmos G, Arencibia JM, et al: Bombesin/gastrin- releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Cancer 1998; 83: 1335 - 1343.
45. Schwartsmann G, DiLeone LP, Horowitz M, et al: A phase I trial of the bombesin/gastrinreleasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs 2006; 24: 403 - 412.
46. Vance ML: Growth-hormone-releasing hormone. Clin Chem 1990; 36: 415 - 420.
47. Frohman LA, Szabo M: Ectopic production of growth hormone-releasing factor by carcinoid and pancreatic islet tumors associated with acromegaly. Prog Clin Biol Res 1981; 74: 259 271.
48. Kahán Z, Arencibia JM, Csernus VJ, et al: Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast endometrial and ovarian cancers. J Clin Endocrinol Metab 1999; 84: 582 589.
49. Khorram O, Garthwaite M, Grosen E, et al: Human uterine and ovarian expression of growth hormone-releasing hormone messenger RNA in benign and malignant gynecological conditions. Fertil Steril 2001; 75: 174 - 179.
50. Kiaris H, Schally AV, Varga JL, et al: Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci USA 1999; 96: 14894 - 14898.
51. Plonowski A, Schally AV, Busto R, et al: Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers. Peptides 2002; 23: 1127-1133. (Pubitemid 34786302)
52. Chopin LK, Herington AC: A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines. Prostate 2001; 49: 116-121. (Pubitemid 32937807)
53. 2+-dependent pathway. Proc Natl Acad Sci USA 2005; 102: 3435 - 3440.
54. Stangelberger A, Schally AV, Rick FG, et al: Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins. Prostate 2012; 72: 555 - 565.
55. Abrahamsson PA: Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999; 6: 503 - 519.
56. Gernone A, Trabucco S, Pagliarulo V, et al: Different expression of somatostatin receptor subtypes in human prostate cancer. J Clin Oncol 2008; 26( suppl): 16148 [abstract].
57. Morichetti D, Mazzucchelli R, Santinelli A, et al: Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation. Int J Imunopathol Pharmacol 2010; 23: 511-522.
58. Harris AG: Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut 1994; 35( 3 suppl): S1 - S4.
59. Kouroumalis E, Skordilis P, Thermos K, et al: Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998; 42: 442 - 447.
60. Wang CH, Tang CW, Liu CL, et al: Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway. World J Gastroenterol 2003; 9: 1904 - 1908.
61. Weckbecker G, Liu R, Tolcsvai L, et al: Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res 1992; 52: 4973 - 4978.
62. Acosta S, Kälkner KM, Thorsson O, et al: Neuroendocrine markers as predictor of octreotide acetate therapy in patients with hormone-refractory prostate cancer. J Clin Oncol 2004; 22( suppl): 4750 [abstract].
63. Xing Z, Zhou Z, Yu R, et al: XAF1 expression and regulatory effects of somatostatin on XAF1 in prostate cancer cells. J Exp Clin Cancer Res 2010; 29: 162.
64. Vainas IG: Octreotide in the management of hormone-refractory prostate cancer. Chemotherapy 2001; 47( suppl 2): 109 - 126.
65. Friedlander TW, Weinberg VK, Small EJ, et al: Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol 2012; 30: 408-414.
66. Tang X, Takekoshi S, Itoh J, et al: Somatostatin analogue inhibits the mobility of prostate carcinoma cells: a new therapeutic method for advanced prostate carcinoma. Int J Oncol 2010; 37: 1077 - 1083.
67. Erten C, Karaca B, Kucukzeybek Y, et al: Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. BJU Int 2009; 104: 107 - 114.
68. Maulard C, Richaud P, Droz JP, et al: Phase I - II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 1995; 36: 259 - 262.
69. Berruti A, Dogliotti L, Mosca A, et al: Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostatespecific antigen, and insulin-like growth factor1 in advanced prostate cancer patients. Prostate 2001; 47:205-211. (Pubitemid 32378372)
70. González-Barcena D, Schally AV, VadilloBuenfil M, et al: Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse. Prostate 2003; 56: 183 - 191.
71. Bolla M, Laramas M, on behalf of AROME: Combined hormone therapy and radiation therapy for locally advanced prostate cancer. Crit Rev Oncol Hematol 2010; epub ahead of print.
72. Nagy A, Schally AV: Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. Gurr Pharm Design 2005; 11: 1167-1180. (Pubitemid 40403375)